DMX 200 for Diabetic Kidney Disease still remains in DXB's pipeline, why?
For patients with higher baseline albuminuria levels (greater than 500 mg/g or 57 mg/mmol), DMX-200 showed a statistically significant 18% reduction in albuminuria compared to placebo (p=0.03)
64% of patients with higher starting albuminuria levels demonstrated a reduction in albuminuria with DMX-200, and 56% achieved a clinically significant reduction of more than 25% compared to the standard of care.
The positive results in patients with higher baseline albuminuria support the progression to further studies to confirm these findings and explore the potential benefits of DMX-200
Is layman terms:
The trial showed significant benefits in patients with higher baseline albuminuria levels. This suggests that DMX-200 could be particularly effective for a subset of patients with more severe kidney damage.
DXB Price at posting:
48.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)